胰腺癌新辅助治疗的研究现状  

Research status of neoadjuvant therapy for pancreatic cancer

作　　者：张文静 刘金爽 王丹[1] 黎清炜 李志伟[1] ZHANG Wenjing;LIU Jinshuang;WANG Dan;LI Qingwei;LI Zhiwei(Harbin Medical University Cancer Hospital,Harbin 150081,China)

机构地区：[1]哈尔滨医科大学附属肿瘤医院,哈尔滨150081

出　　处：《实用肿瘤学杂志》2022年第1期64-68,共5页Practical Oncology Journal

基　　金：国家自然科学基金面上资助项目(编号:81773210)。

摘　　要：胰腺癌是消化系统恶性程度最高的肿瘤。近年来胰腺癌的发病率呈逐年上升趋势,预计在未来10年胰腺癌将成为发达国家癌症死亡的第二大原因。由于诊断时分期较晚,治疗选择有限,胰腺癌的预后极差,只有手术是治愈的唯一方法。为了提高手术切除率并改善预后,新辅助治疗已悄然成为目前胰腺癌治疗的热点问题。但现在胰腺癌的新辅助治疗还未有标准化的治疗方案,本文主要探讨胰腺癌新辅助治疗的研究现状。Pancreatic cancer is the most malignant tumor of the digestive system.In recent years,the incidence of pancreatic cancer has increasing year by year.It is expected that pancreatic cancer will become the second leading cause of cancer death in developed countries in the next decade.Due to the late diagnosis and limited treatment options,the prognosis of pancreatic cancer is extremely poor.Only surgery is the only way to cure.In order to increase the surgical resection rate and improve the prognosis,neoadjuvant therapy has quietly become a hot topic in the treatment of pancreatic cancer.However,there is no standardized treatment plan for neoadjuvant treatment of pancreatic cancer.This article mainly discusses the research status of neoadjuvant treatment of pancreatic cancer.

关 键 词：胰腺癌 新辅助治疗 新辅助化疗 新辅助放化疗 

分 类 号：R735.9[医药卫生—肿瘤]